So a new drug with early good results and early good in low or no side effects. Add a low cost to that mix and it ought to be worth some level of emergency use.
You might want to read your article again, that trial only involved 30 people. The next phase, yet completed, is supposed to involve 155 participants.
So stating that the results might be "good", is one thing, but low or no side effects is a long ways away, especially with the checks & balances in place here in North America.
That it will take a long time to approve of clinical treatments does not follow after the emergency use of the covid injections. The pandemic was crisis enough to allow for emergency use of a few shots (mRNA vaccines)
mRNA vaccine trials involved 10's of thousands of participants, of various ages, gender, race and ethnicity . As one example, Pfizer had a total of 43,000+ participants in their trials.
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints | pfpfizeruscom
Wednesday, November 18, 2020 - 06:59am
- Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group
- Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%
- Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved
- Data demonstrate vaccine was well tolerated across all populations with over 43,000 participants enrolled; no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%
- Companies plan to submit within days to the FDA for EUA and share data with other regulatory agencies around the globe
- The companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021
- Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world
While it is good to see more trials, and the potential for new drugs and/or treatments, those drugs, and treatments will require some close scrutiny, along with further studies to determine their safety across the masses, before they are approved by anyone in the USA, or Canada.